Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 7.4% – Time to Sell?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)’s share price dropped 7.4% during trading on Monday . The stock traded as low as $23.38 and last traded at $23.48. 82,037 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 362,017 shares. The stock had previously closed at $25.36.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DMRA. TD Cowen began coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating for the company. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price for the company. Finally, HC Wainwright initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.43.

Damora Therapeutics, Inc. Common Stock Price Performance

The business has a 50 day simple moving average of $23.72 and a 200 day simple moving average of $25.47. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -4.66 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $40,000. Geode Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $266,000. Virtu Financial LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $49,000. Sigma Planning Corp purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $334,000. Finally, Two Sigma Investments LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $76,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.